Pharmacogenetics in cancer therapy-8 years of experience at the Institute for Oncology and Radiology of Serbia
Нема приказа
Аутори
Cavić, MilenaKrivokuca, Ana
Boljević, Ivana
Brotto, Ksenija
Jovanović, Katarina
Tanić, Miljana
Filipović, Lana
Zec, Manja M.
Malisić, Emma
Janković, Radmila
Radulović, Siniša
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Purpose: Pharmacogenetics is a study of possible mechanism by which an individual's response to drugs is genetically determined by variations in their DNA sequence. The aim of pharmacogenetics is to identify the optimal drug and dose for each individual based on their genetic constitution, i.e. to individualize drug treatment. This leads to achieving the maximal therapeutic response for each patient, while reducing adverse side effects of therapy and the cost of treatment. A centralized pharmacogenetics service was formed at the Institute for Oncology and Radiology of Serbia (IORS) with the aim to provide a personalized approach to cancer treatment of Serbian patients. Methods: Analyses of KRAS mutations in metastatic colorectal cancer, EGFR mutations in advanced non-small cell lung cancer, CYP2D6 polymorphism in breast cancer, DPD polymorphism in colorectal cancer and MTHFR polymorphism in osteosarcoma have been performed by real time polymerase chain reaction (PCR) and PCR-restrictio...n fragment length polymorphism (PCR-RFLP). Results: Mutation testing analyses were successful for 1694 KRAS samples and 1821 EGFR samples, while polymorphism testing was successful for 9 CYP2D6 samples, 65 DPD samples and 35 MTHFR samples. Conclusions: Pharmacogenetic methods presented in this paper provide cancer patients in Serbia the best possible choice of treatment at the moment.
Кључне речи:
EGFR / KRAS / personalized therapy / pharmacogeneticsИзвор:
Journal of BUON, 2016, 21, 5, 1287-1295Издавач:
- Balkan Union of Oncology (B.U.ON.)
Финансирање / пројекти:
Институција/група
Institut za medicinska istraživanjaTY - JOUR AU - Cavić, Milena AU - Krivokuca, Ana AU - Boljević, Ivana AU - Brotto, Ksenija AU - Jovanović, Katarina AU - Tanić, Miljana AU - Filipović, Lana AU - Zec, Manja M. AU - Malisić, Emma AU - Janković, Radmila AU - Radulović, Siniša PY - 2016 UR - http://rimi.imi.bg.ac.rs/handle/123456789/712 AB - Purpose: Pharmacogenetics is a study of possible mechanism by which an individual's response to drugs is genetically determined by variations in their DNA sequence. The aim of pharmacogenetics is to identify the optimal drug and dose for each individual based on their genetic constitution, i.e. to individualize drug treatment. This leads to achieving the maximal therapeutic response for each patient, while reducing adverse side effects of therapy and the cost of treatment. A centralized pharmacogenetics service was formed at the Institute for Oncology and Radiology of Serbia (IORS) with the aim to provide a personalized approach to cancer treatment of Serbian patients. Methods: Analyses of KRAS mutations in metastatic colorectal cancer, EGFR mutations in advanced non-small cell lung cancer, CYP2D6 polymorphism in breast cancer, DPD polymorphism in colorectal cancer and MTHFR polymorphism in osteosarcoma have been performed by real time polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism (PCR-RFLP). Results: Mutation testing analyses were successful for 1694 KRAS samples and 1821 EGFR samples, while polymorphism testing was successful for 9 CYP2D6 samples, 65 DPD samples and 35 MTHFR samples. Conclusions: Pharmacogenetic methods presented in this paper provide cancer patients in Serbia the best possible choice of treatment at the moment. PB - Balkan Union of Oncology (B.U.ON.) T2 - Journal of BUON T1 - Pharmacogenetics in cancer therapy-8 years of experience at the Institute for Oncology and Radiology of Serbia EP - 1295 IS - 5 SP - 1287 VL - 21 UR - https://hdl.handle.net/21.15107/rcub_rimi_712 ER -
@article{ author = "Cavić, Milena and Krivokuca, Ana and Boljević, Ivana and Brotto, Ksenija and Jovanović, Katarina and Tanić, Miljana and Filipović, Lana and Zec, Manja M. and Malisić, Emma and Janković, Radmila and Radulović, Siniša", year = "2016", abstract = "Purpose: Pharmacogenetics is a study of possible mechanism by which an individual's response to drugs is genetically determined by variations in their DNA sequence. The aim of pharmacogenetics is to identify the optimal drug and dose for each individual based on their genetic constitution, i.e. to individualize drug treatment. This leads to achieving the maximal therapeutic response for each patient, while reducing adverse side effects of therapy and the cost of treatment. A centralized pharmacogenetics service was formed at the Institute for Oncology and Radiology of Serbia (IORS) with the aim to provide a personalized approach to cancer treatment of Serbian patients. Methods: Analyses of KRAS mutations in metastatic colorectal cancer, EGFR mutations in advanced non-small cell lung cancer, CYP2D6 polymorphism in breast cancer, DPD polymorphism in colorectal cancer and MTHFR polymorphism in osteosarcoma have been performed by real time polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism (PCR-RFLP). Results: Mutation testing analyses were successful for 1694 KRAS samples and 1821 EGFR samples, while polymorphism testing was successful for 9 CYP2D6 samples, 65 DPD samples and 35 MTHFR samples. Conclusions: Pharmacogenetic methods presented in this paper provide cancer patients in Serbia the best possible choice of treatment at the moment.", publisher = "Balkan Union of Oncology (B.U.ON.)", journal = "Journal of BUON", title = "Pharmacogenetics in cancer therapy-8 years of experience at the Institute for Oncology and Radiology of Serbia", pages = "1295-1287", number = "5", volume = "21", url = "https://hdl.handle.net/21.15107/rcub_rimi_712" }
Cavić, M., Krivokuca, A., Boljević, I., Brotto, K., Jovanović, K., Tanić, M., Filipović, L., Zec, M. M., Malisić, E., Janković, R.,& Radulović, S.. (2016). Pharmacogenetics in cancer therapy-8 years of experience at the Institute for Oncology and Radiology of Serbia. in Journal of BUON Balkan Union of Oncology (B.U.ON.)., 21(5), 1287-1295. https://hdl.handle.net/21.15107/rcub_rimi_712
Cavić M, Krivokuca A, Boljević I, Brotto K, Jovanović K, Tanić M, Filipović L, Zec MM, Malisić E, Janković R, Radulović S. Pharmacogenetics in cancer therapy-8 years of experience at the Institute for Oncology and Radiology of Serbia. in Journal of BUON. 2016;21(5):1287-1295. https://hdl.handle.net/21.15107/rcub_rimi_712 .
Cavić, Milena, Krivokuca, Ana, Boljević, Ivana, Brotto, Ksenija, Jovanović, Katarina, Tanić, Miljana, Filipović, Lana, Zec, Manja M., Malisić, Emma, Janković, Radmila, Radulović, Siniša, "Pharmacogenetics in cancer therapy-8 years of experience at the Institute for Oncology and Radiology of Serbia" in Journal of BUON, 21, no. 5 (2016):1287-1295, https://hdl.handle.net/21.15107/rcub_rimi_712 .